Chief Executive Officer & Member,
Colin Freund has over 20 years’ experience in the pharmaceutical and biotechnology industries, with a primary focus in oncology. Prior to joining Modra Pharmaceuticals, Colin was Chief Executive Officer, QUE Oncology, Inc., which focused on the development of novel therapies for vasomotor symptoms for patients with breast cancer, a non-opioidal therapy for chemo-induced neuropathy, and several early-stage anti-cancer therapies. Before QUE, Colin held senior business and corporate development roles at Transgene SA, Agennix Inc., and GPC Biotech AG, all of which focused on developing novel oncology therapeutics. Prior to joining Double Twist, he was a project manager at the Boston Consulting Group, San Francisco, CA, and London, UK, where he managed assignments in the healthcare and high technology practice areas.
Colin received his MA in Economics and Management Studies from the University of Cambridge (UK), and his MBA from Stanford University (USA).